Federal Challenges to DOJ Program Reveal Hidden Ties to Major Corporate Lobbying Groups
A new wave of federal challenges to DOJ programs has unearthed evidence that a controversial initiative, ostensibly designed to police corporate fraud, is being steered behind the scenes by the very entities it claims to target. Leaked internal documents suggest that key policy decisions were shaped by lobbyists for Big Pharma and Wall Street, raising the question: who truly benefits from this oversight? Critics argue the program's true aim is to consolidate control, not enforce accountability.